RU2018113521A - Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b - Google Patents
Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b Download PDFInfo
- Publication number
- RU2018113521A RU2018113521A RU2018113521A RU2018113521A RU2018113521A RU 2018113521 A RU2018113521 A RU 2018113521A RU 2018113521 A RU2018113521 A RU 2018113521A RU 2018113521 A RU2018113521 A RU 2018113521A RU 2018113521 A RU2018113521 A RU 2018113521A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- amino acid
- influenza virus
- acid sequence
- residues
- Prior art date
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims 27
- 229920001184 polypeptide Polymers 0.000 title claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 17
- 230000028993 immune response Effects 0.000 title claims 6
- 206010022000 influenza Diseases 0.000 title claims 2
- 241000700605 Viruses Species 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 101710154606 Hemagglutinin Proteins 0.000 claims 17
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 17
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 17
- 101710176177 Protein A56 Proteins 0.000 claims 17
- 239000000185 hemagglutinin Substances 0.000 claims 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 7
- 102000005348 Neuraminidase Human genes 0.000 claims 6
- 108010006232 Neuraminidase Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
- 108060003393 Granulin Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16223—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261596014P | 2012-02-07 | 2012-02-07 | |
| US61/596,014 | 2012-02-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014135703A Division RU2653756C2 (ru) | 2012-02-07 | 2013-02-06 | Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018113521A true RU2018113521A (ru) | 2019-03-04 |
Family
ID=48947966
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018113521A RU2018113521A (ru) | 2012-02-07 | 2013-02-06 | Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b |
| RU2014135703A RU2653756C2 (ru) | 2012-02-07 | 2013-02-06 | Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014135703A RU2653756C2 (ru) | 2012-02-07 | 2013-02-06 | Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9234008B2 (enExample) |
| EP (1) | EP2812348A4 (enExample) |
| JP (1) | JP6336915B2 (enExample) |
| KR (1) | KR20140127827A (enExample) |
| CN (1) | CN104136456A (enExample) |
| AU (2) | AU2013217166B2 (enExample) |
| BR (1) | BR112014018884A2 (enExample) |
| CA (1) | CA2863981A1 (enExample) |
| HK (1) | HK1203524A1 (enExample) |
| IN (1) | IN2014DN05805A (enExample) |
| MX (1) | MX2014009148A (enExample) |
| RU (2) | RU2018113521A (enExample) |
| SG (1) | SG11201404653UA (enExample) |
| WO (1) | WO2013119683A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2811103C (en) * | 2010-09-14 | 2020-01-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| JP6113155B2 (ja) | 2011-06-20 | 2017-04-12 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原 |
| MY180109A (en) | 2012-02-13 | 2020-11-23 | Univ Pittsburgh Commonwealth Sys Higher Education | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| EP2831094B1 (en) * | 2012-03-30 | 2018-06-13 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses |
| JP2016505538A (ja) | 2012-11-27 | 2016-02-25 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Ｈ１ｎ１インフルエンザに対する計算で最適化した広い反応性を示す抗原 |
| WO2016100926A1 (en) * | 2014-12-19 | 2016-06-23 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| AU2016270979B2 (en) | 2015-06-02 | 2020-11-12 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| WO2016201127A1 (en) | 2015-06-09 | 2016-12-15 | Sanofi Pasteur, Inc. | Methods of optimizing nucleotide sequences encoding engineered influenza proteins |
| WO2017053374A1 (en) * | 2015-09-21 | 2017-03-30 | Oregon Health & Science University | Design and characterization of influenza vaccines |
| EP3464328A1 (en) | 2016-06-02 | 2019-04-10 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
| EP3464327A1 (en) * | 2016-06-03 | 2019-04-10 | Sanofi Pasteur Inc. | Modification of engineered influenza hemagglutinin polypeptides |
| US20210225457A1 (en) * | 2018-07-13 | 2021-07-22 | University Of Georgia Research Foundation | Methods for generating pan-epitopic immunogens of influenza h3 virus, compositions and methods of use thereof |
| CN121499810A (zh) * | 2018-09-28 | 2026-02-10 | 剑桥企业有限公司 | 疫苗和方法 |
| WO2024167855A1 (en) * | 2023-02-06 | 2024-08-15 | Emergent Product Development Gaithersburg Inc. | Influenza hemagglutinin constructs and compositions |
| WO2025179103A1 (en) * | 2024-02-23 | 2025-08-28 | University Of Georgia Research Foundation, Inc. | Pentavalent and octavalent influenza virus immunogens, compositions and methods of use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5662907A (en) | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| DE69535905D1 (de) | 1994-07-15 | 2009-02-26 | Coley Pharm Group Inc | Immunomodulatorische Oligonukleotide |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| WO1998052581A1 (en) | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
| JP2002510644A (ja) | 1998-04-03 | 2002-04-09 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物 |
| AU2002211948B2 (en) | 2000-03-02 | 2007-09-13 | Emory University | DNA expression vectors and methods of use |
| US20050181459A1 (en) | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
| US7566458B2 (en) * | 2003-06-16 | 2009-07-28 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| CA2598884A1 (en) | 2005-02-24 | 2006-10-05 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
| US20090327170A1 (en) | 2005-12-19 | 2009-12-31 | Claudio Donati | Methods of Clustering Gene and Protein Sequences |
| US20080045472A1 (en) | 2006-03-31 | 2008-02-21 | Council Of Scientific And Industrial Research Bharat Biotech | Targets for human micro rnas in avian influenza virus (h5n1) genome |
| WO2007130327A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Influenza virus-like particle (vlp) compositions |
| WO2007134327A2 (en) * | 2006-05-15 | 2007-11-22 | Sea Lane Biotechnologies, Llc. | Neutralizing antibodies to influenza viruses |
| US8980281B2 (en) | 2006-09-05 | 2015-03-17 | Academia Sinica | High-yield transgenic mammalian expression system for generating virus-like particles |
| CA2663388C (en) | 2006-09-07 | 2017-01-17 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| AU2007304883B2 (en) | 2006-10-04 | 2013-09-05 | The University Of Queensland | VLP based vaccine delivery system |
| MX2009013008A (es) * | 2007-05-31 | 2010-06-09 | Vacunas para la influenza. | |
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| US8071561B2 (en) | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
| EP2217064A4 (en) * | 2007-11-12 | 2012-10-03 | Univ Pennsylvania | NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES |
| EA034733B1 (ru) * | 2008-01-21 | 2020-03-13 | Медикаго Инк. | Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение |
| US7981428B2 (en) | 2008-01-23 | 2011-07-19 | Academia Sinica | Flu vaccines and methods of use thereof |
| US20120034253A1 (en) | 2008-09-25 | 2012-02-09 | Fraunhofer Usa, Inc. | Influenza Vaccines, Antigens, Compositions, and Methods |
| WO2010036948A2 (en) | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
| KR101715418B1 (ko) | 2009-04-03 | 2017-03-10 | 메리얼 인코포레이티드 | 뉴캐슬 질환 바이러스-벡터를 이용한 조류 백신 |
| US20110159031A1 (en) * | 2009-12-22 | 2011-06-30 | Baxter International Inc. | Vaccine to Influenza A Virus |
| US8298820B2 (en) * | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| CA2811103C (en) | 2010-09-14 | 2020-01-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for influenza |
| JP6113155B2 (ja) | 2011-06-20 | 2017-04-12 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原 |
-
2013
- 2013-02-06 US US14/376,689 patent/US9234008B2/en active Active
- 2013-02-06 BR BR112014018884A patent/BR112014018884A2/pt not_active IP Right Cessation
- 2013-02-06 RU RU2018113521A patent/RU2018113521A/ru not_active Application Discontinuation
- 2013-02-06 JP JP2014555853A patent/JP6336915B2/ja not_active Expired - Fee Related
- 2013-02-06 CN CN201380008469.3A patent/CN104136456A/zh active Pending
- 2013-02-06 IN IN5805DEN2014 patent/IN2014DN05805A/en unknown
- 2013-02-06 SG SG11201404653UA patent/SG11201404653UA/en unknown
- 2013-02-06 RU RU2014135703A patent/RU2653756C2/ru not_active IP Right Cessation
- 2013-02-06 CA CA2863981A patent/CA2863981A1/en not_active Abandoned
- 2013-02-06 EP EP13747212.2A patent/EP2812348A4/en not_active Withdrawn
- 2013-02-06 KR KR1020147023368A patent/KR20140127827A/ko not_active Withdrawn
- 2013-02-06 AU AU2013217166A patent/AU2013217166B2/en not_active Ceased
- 2013-02-06 HK HK15104019.2A patent/HK1203524A1/xx unknown
- 2013-02-06 MX MX2014009148A patent/MX2014009148A/es unknown
- 2013-02-06 WO PCT/US2013/024957 patent/WO2013119683A1/en not_active Ceased
-
2017
- 2017-06-29 AU AU2017204454A patent/AU2017204454A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014018884A2 (pt) | 2017-07-04 |
| RU2014135703A (ru) | 2016-03-27 |
| EP2812348A4 (en) | 2015-12-30 |
| HK1203524A1 (en) | 2015-10-30 |
| JP2015506705A (ja) | 2015-03-05 |
| AU2017204454A1 (en) | 2017-07-20 |
| SG11201404653UA (en) | 2014-09-26 |
| MX2014009148A (es) | 2014-09-22 |
| RU2653756C2 (ru) | 2018-05-14 |
| CA2863981A1 (en) | 2013-08-15 |
| AU2013217166B2 (en) | 2017-04-06 |
| US9234008B2 (en) | 2016-01-12 |
| EP2812348A1 (en) | 2014-12-17 |
| AU2013217166A1 (en) | 2014-08-28 |
| IN2014DN05805A (enExample) | 2015-05-15 |
| CN104136456A (zh) | 2014-11-05 |
| KR20140127827A (ko) | 2014-11-04 |
| JP6336915B2 (ja) | 2018-06-06 |
| WO2013119683A1 (en) | 2013-08-15 |
| US20150044247A1 (en) | 2015-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018113521A (ru) | Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b | |
| RU2017141447A (ru) | Рекомбинантные полипептиды гемагглютинина (ha) вируса гриппа, композиции, содержащие их, и способы вызова иммунного ответа в отношении вируса гриппа h1n1 | |
| RU2014101401A (ru) | Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств | |
| JP6957580B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| JP2015506705A5 (enExample) | ||
| US11485759B2 (en) | Polypeptides for use in self-assembling protein nanostructures | |
| US20200330584A1 (en) | Computationally optimized broadly reactive antigens for influenza | |
| RU2015124805A (ru) | Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вируса гриппа h1n1 | |
| HRP20171213T1 (hr) | Glikoproteinske čestice nalik virusu (vlp) bjesnoće | |
| RU2019139064A (ru) | Композиции и способы для лечения цитомегаловируса | |
| JP2016505538A5 (enExample) | ||
| US9896484B2 (en) | Influenza virus recombinant proteins | |
| Li et al. | A self-assembled nanoparticle vaccine elicits effective neutralizing antibody response against EBV infection | |
| CN101899461A (zh) | 一种编码甲型流感病毒NP蛋白和M2e多肽的融合基因 | |
| CN107344969A (zh) | 一种纳米流感疫苗及构建方法和应用 | |
| Krammer et al. | Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis | |
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| CN115850395A (zh) | 一种流感病毒通用型纳米颗粒疫苗及其制备方法 | |
| Wu et al. | Hemagglutinin-encoded mRNA vaccine confers efficient protection against H3N8 avian influenza virus in Mice | |
| Kang et al. | Rapid development of SARS-CoV-2 receptor binding domain-conjugated nanoparticle vaccine candidate | |
| CN117045781A (zh) | 一种基于分子佐剂的广谱型h9亚型禽流感ha亚单位黏膜疫苗及其制备方法和应用 | |
| WO2024199469A1 (zh) | 具有稳定融合前构象的呼吸道合胞病毒f蛋白 | |
| CN109821014A (zh) | 一种多抗原仿生流感疫苗及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20160208 |